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Abstract 
Herpesvirus entry into cells begins when viral membrane glycoproteins bind to cellular 
receptors.  This receptor binding elicits a cascade of interactions among conserved viral 
membrane glycoproteins that triggers virus-cell membrane fusion.  Details of the viral protein 
interactions are not well understood because they are likely transient and/or low affinity. 
Proximity biotinylation (ProB) is a promising technique for dissecting the glycoprotein 
interactions required for entry.  In ProB, one protein is linked to a bacterial biotin ligase and a 
second protein is linked to a target 15 amino acid acceptor peptide (AP).  If the proteins interact, 
the ligase on the first protein catalyzes site-specific biotinylation of the AP on the second protein.  
Evidence of interaction can be detected by western blotting with streptavidin to visualize 
biotinylated proteins.  Labeling is covalent and occurs within live cells, thus weak and transient 
interactions can be detected.  The short length of AP reduces the risk of altering the native 
conformation of the glycoproteins.   
Sensitivity and specificity are concerns for all interaction assays.  To establish optimal 
conditions for ProB, the biotin ligase and AP were linked to herpes simplex virus gD and Epstein 
Barr virus gB.  These oligomeric herpesvirus proteins do not interact functionally and assaying 
for a heterotypic interaction between them serves as a negative control to demonstrate specificity 
of the ProB assay.  Homotypic interactions between their monomers serve as a positive control to 
demonstrate sensitivity.  The positive controls show strong biotinylation, indicating that 
proximity of viral membrane proteins can be detected.  Unexpectedly, the negative controls also 
showed biotinylation, albeit at a lower level.  These results demonstrate the special circumstances 
that must be considered when examining interactions among proteins that are constrained within 
the two-dimensional boundaries of a membrane.  The lab is currently investigating ways to limit 
the heterotypic interaction and designing constructs to further test ProB validity for membrane-
restricted protein interactions.   
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Abbreviations 
 
CHO   Chinese hamster ovary  
FBS  Fetal bovine serum 
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BME  Beta-mercaptoethanol 
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I. Review of Literature  
 
A. The Herpesviridae Family  
Herpesviruses cause a lifelong infection of a large variety of animal hosts, and the 
average person carries multiple herpesviruses (36, 70). Herpesviruses are double-stranded linear 
DNA viruses with genomes ranging from 120 to 230 kb in length (60). The herpesvirus genome 
is encased in a proteinaceous capsid that is enclosed within a lipid envelope (60). Embedded in 
this envelope are approximately a dozen glycoproteins that are responsible for interactions with 
the host cell (60). The space between the capsid and the envelope contains proteins called 
tegument that are essential to the establishment of infection after entry into the cell, for example 
transcription factors (60).  
There are eight human herpesviruses that cause a variety of diseases, ranging from cold 
sores to cancers. The Herpesviridae family is divided into three subfamilies—alpha, beta, and 
gammaherpesviruses. This project focuses on the human alphaherpesvirus herpes simplex virus 1 
and the human gammaherpesvirus Epstein-Barr virus. Alphaherpesviruses are characterized by 
their ability to establish lifelong latent infections in the peripheral nervous system of a host. An 
infection is defined as latent when the virus is present but dormant and producing no overt 
symptoms.  Alphaherpesviruses have a short growth cycle and rapid spread. The human viruses 
within the alphaherpesvirus subfamily include herpes simplex virus 1 (HSV1), herpes simplex 
virus 2 (HSV2), and varicella-zoster virus (VZV), the causative agents of cold sores, genital 
lesions, and chickenpox respectively. Gammaherpesviruses are characterized by the viral growth 
in epithelial and B- or T- lymphocytes. The human viruses within the gammaherpesvirus class are 
Epstein-Barr virus (EBV) (51) and human herpesvirus 8 (HHV-8). EBV causes infectious 
mononucleosis, Burkitt’s lymphoma, and nasopharyngeal carcinoma, where as HHV-8 causes 
Kaposi’s sarcoma.   
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Although the typical course of herpesvirus infection results in modest symptoms, serious 
and potentially life-threatening complications can occur. Gammaherpesvirus infections may be 
asymptomatic, but they may also result in the cancers mentioned above.  Complications from 
alphaherpesvirus infection include herpes encephalitis, herpes meningitis, ocular herpes, 
gingivastomatitis, shingles, and postherpetic neuralgia. The severity of these complications 
highlights the importance of understanding all aspects of the virus life cycle, including virus entry 
into cells, replication and assembly within cells, release from cells, spread through tissues and 
interactions with the immune system. This thesis will focus on HSV1 and the interactions of 
envelope glycoproteins with the host cell during entry, the first step of viral infection.  The entry 
step is an attractive target for antiviral intervention because if the virus is prevented from entering 
the cell, the infection is never established. 
Herpesviruses use a conserved set of machinery to enter into cells. The glycoproteins for 
HSV1 and HSV2 are so similar that they are functionally interchangeable. Learning about HSV1 
is directly applicable to HSV2 and other enveloped viruses, such as paraymyxoviruses, which 
also encode for a receptor binding and fusion of separate glycoproteins. 
 
B. Epidemiology  
 HSV1 and HSV2 cause genital herpes, however HSV2 is the most common cause. In 
2003, more than 500 million people worldwide were infected with HSV2 and more women than 
men were infected (44). In the 1970s and 1980s, over 30% of women diagnosed with genital 
herpes were infected with HSV1 (69). HSV1 is now responsible for 40% of new cases of genital 
herpes (17). In a study tracking primary HSV infection in women for 20 months, 3.7% of the 
women (127 out of 3438 participants) were infected with HSV1 while only 1.6% were infected 
with HSV2 (9).  Infection rates differ greatly between racial groups. From the study tracking 
women for 20 months, HSV2 infections were found to vary significantly among racial groups: 
74% black, 40% Hispanic, and 23% white (9). Other studies have found similar results. HSV2 
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seroprevalence was found in 21.9% of the overall population (22). The individuals with HSV2 
infections also varied among racial groups: 45.9% black, 22.3% Hispanic, and 17.6% white (22). 
Overall, HSV1 and HSV2 are increasing in prevalence. 
 
C. HSV1 Entry Glycoproteins 
HSV may enter cells through two pathways, depending on cell type. HSV1 virions are 
able to infect lymphocytes, epithelial cells, fibroblasts, and neurons. There are two entry 
pathways both requiring viral glycoproteins to induce fusion: fusion can occur at the cell surface 
at a neutral pH or in the endosome in a low pH-dependent manner. (48, 52). Many aspects of 
herpes simplex virus entry into cells are understood, but the overall sequence of events and 
interactions among entry proteins is disputed.  For HSV1, a small set of glycoproteins in the viral 
membrane envelope (gB, gD, gH, and gL) are both necessary and sufficient for fusion of the virus 
with the host cell (56, 68) (Fig.1). Glycoproteins gD, gB, gH, and gL are the minimum viral 
requirement needed for entry into the cell and viruses deleted for any of these glycoproteins fail 
to enter cells (56, 68).  The nature of the interaction between these proteins has yet to be defined, 
including the order of interactions and the site of interactions. 
 In the first step of entry, the virus tethers to heparan sulfate proteoglycans on the host cell 
surface via the viral glycoproteins gB and gC. Although the gB and gC interaction with heparan 
sulfate enhance the efficiency of virus entry, these interactions are not required for entry (30, 41).  
Removal of heparan sulfate binding capacity does not inactivate the virus. Binding to heparan 
sulfate does not trigger the conformational changes in the viral proteins that are required to cause 
fusion of the viral envelope with the cellular membrane. 
Fusion is triggered by the binding of gD to a specific cellular receptor(66).  The two 
widely studied receptors that bind to gD include nectin-1 and herpesvirus entry mediator 
(HVEM). Nectin-1 is thought to be a critical herpesvirus receptor, and it is expressed on neurons; 
neurons are a key cell type for HSV1 infection as this is the cell type in which HSV1 establishes  
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  Figure 1. Interactions that mediate HSV entry. HSV entry into a cell requires four essential 
glycoproteins found on the viral envelope: gD, gH, gL, and gB.  These glycoproteins both are necessary 
and sufficient for the fusion of the viral lipid envelope with the cell membrane.  In the current model, 
virus entry is initiated when gD, which exists as a dimer, binds to a specific receptor on the membrane of 
the host cell.  The most common receptors are nectin-1 and herpes virus entry mediator (HVEM).  
Receptor-binding results in conformational changes in gD that have been observed using 
crystallography.  Due to structural similarity between gB and other viral fusion proteins, gB is believed 
to be responsible for physically inserting into the host cell membrane and then refolding to execute 
membrane fusion.  gH and gL form a heterodimer, and the role gH/gL is less clear.  gH/gL and gD alone 
are insufficient for fusion and gH/gL does not resemble any known fusion protein.  Thus, gH/gL likely 
plays a role in transmitting a signal to gB to trigger the fusion event.  How gD interacts with gH/gL 
and/or gB to trigger fusion of the virus with the target cell after receptor binding is poorly understood.  
The interactions among the glycoproteins are hard to capture, presumably because they are either low 
affinity or transient interactions. 
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latency (38, 58). Transgenic mouse models of HSV1 infection have demonstrated that deletion of 
nectin-1 greatly inhibits virus infection and spread through the host (35, 37, 65). The nectin 
family of molecules function in intercellular adhesion. HVEM, formerly known as HveA, is a 
member of the tumor necrosis factor receptor family and is expressed on a variety of tissues, 
including immune cells (50).  Transgenic mouse models of HSV1 infection have suggested that 
HVEM is a dispensable receptor because HSV1 infection in the absence of HVEM proceeds at 
near-wild type manner (35, 37, 65). The reason why HSV1 retains the ability to use HVEM as a 
receptor is unclear. In fact, a point mutation in gD is sufficient to eliminate HVEM binding 
without preventing nectin-1 usage (39).  The retention of HVEM binding by gD suggests that 
HVEM contributes to the virus life cycle in some manner, perhaps in an as-of-yet undefined 
immune evasion strategy. A third receptor that gD can bind is a 3-O-sulfated heparan sulfate, a 
type of heparan sulfate (61). The contribution of 3-O-sulfated heparan sulfate to HSV1 infection 
of an animal remains unclear.  
 HSV1 gD has 369 amino acid residues and forms a dimer (39). gD is unique to 
alphaherpesviruses and other families of herpesviruses use other receptor binding proteins. For 
example, EBV uses the receptor binding protein, gp42 that communicates with gH/gL and gB for 
entry into B cells. The crystal structure of gD has been determined alone and in complex with the 
receptors HVEM or nectin-1 (11, 18, 39). Glycoprotein gD has no sequence homology to other 
proteins, however it has a V-like immunoglobulin fold at its core from residues 56 to 184 (11). 
Immunoglobulin-like folds are found on many proteins in the immune system and proteins 
involved in cell-cell recognition and adhesion in nervous system. The residues on gD that bind 
HVEM are located entirely on an N-terminal extension that is supported by the core of the gD 
molecule (11). The binding site of nectin-1 is distinct from but overlaps with the binding site of 
HVEM. Nectin-1 binds to residues within the gD core as well as residues near the gD N-terminus 
(18). Specifically, the gD residue tyrosine 38 is critical for nectin-1 binding (18). The gD C-
terminus is a flexible structural element that is able to interfere with receptor binding (39). It has 
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been suggested that the C-terminus of gD normally occludes the receptor-binding site and that 
upon receptor binding, this gD C-terminus is displaced.  This movement of the gD C-terminus 
may be the signal that triggers the next step of entry. The protein(s) that gD interacts with after 
receptor binding has not been fully established. 
 gB is a 904 residue protein that is conserved among all herpesviruses and exists as a 
trimer (29).  The crystal structure of HSV1 gB revealed a striking structural similarity to a 
rhabdovirus fusion protein, despite the fact that gB has no sequence homology to this protein (29, 
59). The ectodomain of EBV gB has also been characterized (7). This structural similarity to a 
known fusion protein strongly suggests that gB is also a fusion protein. Fusion proteins are 
responsible for physically fusing the viral membrane with the cellular membrane. They are 
expressed initially in a prefusion conformation.  Upon triggering, they insert hydrophobic 
residues (called fusion loops or fusion peptides) into a target membrane and then refold into a 
postfusion conformation, dragging the viral membrane and cellular membrane together to force 
membrane fusion.  The crystal structure of gB reveals putative fusion loops and these 
hydrophobic loops are critical for fusion (29). gB represents a class III fusion protein, 
characterized by the presence of fusion loops and a coiled-coil domain (16, 29). Mutations in a C-
terminal region of the gB ectodomain that contacts the coiled-coil domain inhibit the ability of gB 
to execute fusion, suggesting that residues in this C-terminal region may provide a driving force 
for gB refolding into its postfusion conformation (16). gB is reported to be to be required for 
HSV1 nuclear egress, the process wherein the capsids leave the nucleus after being loaded with 
genome. The requirement of gB for nuclear egress may indicate that gB mediates fusion of an 
initial virion envelope (comprised of the inner nuclear membrane) with outer nuclear membrane. 
When the fusion loops of gB were mutated, the virus was unable to exit the perinuclear space 
(71). Unexpectedly, gB and gH were reported to have redundant functions in nuclear egress, a 
redundancy that does not occur during virus entry (71).  
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 The glycoproteins gH and gL are found in a heterodimer (32). gL is required for correct 
folding, surface expression, and function of gH, and thus the two proteins are treated as one 
functional unit, referred to as gH/gL (63). Prior to the solution of the crystal structure of gB, 
gH/gL was thought to be a viral fusion protein. This idea stemmed from four reports. First, as 
mentioned above, gH was reported to function in nuclear egress.  Second, some stretches in gH 
resemble hydrophobic and helical peptides that are present in known fusion proteins (23, 26). 
Third, gD and gH/gL were reported to be sufficient for hemifusion in the absence of gB (64). 
Hemifusion is an intermediate step in fusion wherein the outer leaflets of the two lipid bilayers 
mix prior to the formation of a fusion pore. Fourth, gH/gL from the alphaherpesvirus VZV was 
reported to be sufficient alone for cell-to-cell fusion (19).  The general consensus in the field now 
is that gH/gL is not a fusion protein (13). More recent studies report that both VZV gH/gL and gB 
are required for fusion (45) and that gH/gL is insufficient for hemifusion (34).  
The crystal structure of the gH/gL complex from HSV2 were determined recently (13). 
There are crystal structures of EBV gH/gL and a partial structure of pseudorabies gH as well (6, 
46). The sequences of HSV1 gH and gL are highly homologous to those of HSV2 gH and gL, so 
the structure of HSV1 gH/gL is likely very similar to that of HSV2 gH/gL. HSV2 gH/gL has a 
boot shaped structure. The glycoprotein gH has three domains (H1-H3). H1 is an N-terminal 
domain that binds to gL; H2 is a central helical domain; and H3 contains a C-terminal β-sandwich 
domain (13). The H3 domain sequence is highly conserved among herpesviruses and may play a 
functionally important role. gH is required for the proper folding of gL since gL does not have a 
stable core itself. Glycoprotein gL has four cysteines that form two disulfide bonds that are 
conserved among other herpesviruses (13). gH has been shown to bind αvβ3 intergrins molecules 
at a Arg-Gly-Asp (RGD) motif (55). Other viruses use intergrins as entry receptors, including 
HHV8. This may not be the case for HSV since mutations in the RGD motif did not limit 
infection in vitro (55). Intergrin-gH interactions may play a role in entry in other cell types in 
vivo. gH/gL is proposed to transmit activating signals to gB, allowing gB execute membrane 
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fusion (63). The function of gH/gL is still unknown since it does not function as the fusion 
protein yet is necessary for HSV fusion.  
 
D. EBV entry glycoproteins 
 EBV and HSV1 share three conserved essential entry glycoproteins—gB, gH, and gL. 
HSV1 requires gD to bind to a cellular receptor to trigger fusion; however, EBV does not encode 
a gD.  Entry of EBV, like HSV, is cell type dependent; EBV can infect B cells, epithelial cells, 
and monocytes (43). Entry into B cells occurs through viral glycoproteins interacting with a 
cellular receptor either on the cell surface or in the endosome in a pH-dependent fashion (14, 47). 
For B cell entry, glycoprotein 42 (gp42) replaces the function of HSV1 gD and binds to the 
cellular receptor human leukocyte antigen class II (HLA class II) (42).  gp42 is cleaved near the 
N-terminus but remains attached to the virion due to binding to gH/gL (57). Conformational 
changes in gp42 and/or gH/gL trigger gB to insert fusion loops into the B cell. gB undergoes a 
conformational change causing fusion between the viron membrane and B cell membrane.  
EBV entry into epithelial cells occurs differently. gp42 is not required for epithelial cells 
entry, and gp42 inhibits entry into epithelial cells.  EBV entry into epithelial cells requires only 
gH/gL and gB.  gH/gL is responsible for attachment to the epithelial cells. Some evidence shows 
that gH/gL binds to αν integrins on epithelial cells(49, 72, 73). After receptor-binding, gH/gL is 
able to interact with gB, causing gB to insert its fusion loops into the epithelial cell membrane 
(12). gB undergoes a conformational change causing fusion of the two membranes.    
EBV has evolved a mechanism to alter tropism of the virus from epithelium to B cells 
and back to epithelium in a host. The viruses made in B cells have low amount of gp42 since the 
3-part complex (gHgLgp42) is degraded in the endoplasmic reticulum if the complex interacts 
with HLA class II (10). The viruses made in epithelial cells have high amounts of gp42 since 
these cells do not have MHC class II molecules (10). The virus from B cells is more infectious to 
epithelial cells; while, the virus from epithelial cells is more infectious to B cells.  
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E. Glycoprotein Interactions 
 The glycoproteins gD, gB, and gH/gL are required for HSV1 entry and their interactions 
are an active area of research. Using chemical cross-linkers, heterodimers of gB-gC, gC-gD, and 
gD-gB have been detected (27, 28).  Co-immunoprecipitation of the glycoproteins is challenging 
because the interactions are likely transient and/or low affinity and the proteins may disassociate 
during a pull-down assay. The glycoproteins exist in native membrane-anchored states on the 
virion envelope and the detergents required for a pull-down assay may perturb the normal 
interactions. One research group has reported using a pull-down assay to detect all of the 
glycoproteins interacting with all of the other glycoproteins (25).  
Given the limitations of the pull-down assay, a new method emerged to study 
glycoprotein interactions—bimolecular fluorescence complementation (BiFC). BiFC allows for 
direct visualization of protein interactions in a living cell. One candidate protein is fused with the 
N-terminal portion of a fluorescent protein and another candidate protein is fused with the C-
terminal portion of the fluorescent protein. The interaction between two candidate proteins drives 
the formation of a functional fluorescent complex as the two fragments of the fluorescent protein 
are brought into proximity (31). Visualization of physical interactions is possible in the normal 
environment of a living mammalian cell.  BiFC has known complications. Use of a fluorescent 
tag can drive proteins to the wrong cellular compartment or cause the proteins to misfold (67). In 
addition, false positives are a concern. The two portions of the fluorescent protein have intrinsic 
affinity for one another, and this affinity can contribute spuriously to interactions between 
proteins (15, 31). The fluorescent halves do not come apart after interacting with one another. 
False negatives are also possible since the fluorescent protein fragments can sterically block 
protein-protein interactions (31). Another concern is that BiFC is characterized through 
microscopy, which can be more subjective than western blotting. 
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BiFC has been used to study glycoprotein interactions in HSV1. Initially, two research 
groups using BiFC reported that gD is able to interact with gB in the absence of gH/gL (2). The 
inverse was also true; gD was able to interact with gH/gL in absence of gB (2). Most notably, 
gH/gL was able to interact with gB, but only in the presence of gD, suggesting that gD binding to 
receptor triggered a gH/gL-gB interaction (2, 4). These BiFC studies supported a proposed model 
in which gD binding to receptor causes a conformational change in gD that activates gH/gL to 
interact with gB which then executes membrane fusion (3, 16) (Fig. 1).  
This proposed model stands as the generally accepted model of herpesvirus entry 
however further studies using BiFC have clouded the model.  After further study, one of the 
research groups above used BiFC to demonstrate that gB can bind to gH/gL in the absence of gD 
(4, 5). Later studies used BiFC to probe the sites of glycoprotein interactions using mutant 
glycoproteins and monoclonal antibodies that block virus entry (1). These studies found that 
gH/gL failed to interact with a gB carrying mutations in its fusion loops. This result led the 
researchers to propose that gB inserts its fusion loops into the host cell membrane prior to an 
interaction with gH/gL, a suggestion that leaves the signal that triggers gB to insert its fusion 
loops into the host cell membrane unaccounted for. In a study on paramyxoviruses, BiFC resulted 
in fluorescence when the receptor-binding protein was co-expressed with its fusion protein but  
also when it was co-expressed with unrelated BiFC labeled constructs, showing BiFC may be 
driving the interactions (15). These conflicting results highlight concerns with the BiFC technique 
and the leave questions regarding the sequence of interactions among HSV1 glycoproteins. 
 
F. Proximity Biotinylation 
With the false positive and false negative concerns of BIFC, the interactions between the 
HSV1 proteins and the sequence of events are unclear. Another new technique, proximity 
biotinylation, can be used to characterize the protein-protein interactions. Proximity biotinylation 
uses an enzyme and substrate pair to detect candidate protein interactions. One candidate protein 
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is tagged with the Escherichia coli biotin ligase enzyme (BirA), and another candidate protein is 
tagged with a 15 amino acid acceptor peptide substrate (AP). If BirA and AP come into close 
proximity, BirA will covalently ligate biotin to the AP (Fig. 2). The interaction can be observed 
by microscopy using fluorescently labeled streptavidin or by western blot using streptavidin to 
visualize the biotinylated proteins. Multiple versions of the AP target peptide with differing 
affinities for BirA are available, and these options allow for optimization of signal over 
background noise (21, 67).  
Proximity biotinylation is a promising technique for many reasons. Labeling can be done 
in live cells. Cells can be transfected with different combinations of viral glycoproteins in the 
presence and absence of receptor. The interaction between biotin and streptavidin is high affinity 
and highly sensitive. Endogenous mammalian biotin ligase does not recognize the AP target 
peptide. A low false positive rate across a wide range of protein expression levels has been 
reported (21). Since the AP is only 15 amino acids compared to the large BiFC fluorescent tags, it 
is less likely to alter the glycoprotein function. BirA and the AP are able to move apart after an 
interaction so proteins are free to move in the membrane, making it an ideal technique for 
transmembrane protein interactions. Another advantage to ProB is that the biotin is covalently 
linked to the AP tag permanently tagging the protein with biotin. Since detection of biotinylated 
proteins is done on the cell lysates through western blotting, the interaction between proteins can 
be clearly identified. ProB has the potential to be a useful protein-protein interaction technique 
without the need for microscopy, the ability to use western blotting, no time delay, or the use of a 
fluorophore. This technique is worth optimizing to use for transient, transmembrane interactions. 
ProB has potential to characterize herpesvirus glycoproteins interactions due to these lucrative 
advantages.   
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G. Project Overview 
The goal of this thesis project is to optimize a proximity biotinylation assay and 
determine whether it can be used to study the herpesvirus entry glycoprotein interactions. One 
aim is to determine if biotinylation is detectable through the use of positive and negative controls. 
The other aim is to determine the optimal conditions of ProB assay. Interactions between the 
subunits of known oligomers serve as the positive controls.  Coexpression of HSV gD constructs 
linked to BirA and AP is expected to result in biotinylation because gD oligomerizes (homotypic 
interaction).  Similarly, coexpression of EBV gB linked to BirA and APm serves as a positive 
control (homotypic interaction).  Coexpression of proteins that are not expected to interact serve 
as negative controls (heterotypic interactions).  HSV gD and EBV gB do not functionally interact 
and thus coexpression of HSV gD and EBV gB constructs linked to BirA or AP is not expected to 
result in biotinylation.  By establishing positive and negative controls, ProB could be used to 
detect the glycoprotein interactions between HSV gB, gD, and gH/gL before and after gD binds a 
cellular receptor, and before and after fusion occurs.  
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Figure 2. Proximity biotinylation. Proximity biotinylation (ProB) is a technique wherein an 
enzyme and substrate pair is used to determine if an interaction occurs. One target protein is 
tagged with Escherichia coli biotin ligase enzyme (BirA) and the other protein is tagged with its 
substrate, a 15 amino acid acceptor peptide (AP). If an interaction occurs between the two target 
proteins, BirA will covalently ligate biotin to the AP. Streptavidin, which has a high affinity for 
biotin, can then be used to visualize the biotinylated target proteins by western blot or 
fluorescence microscopy.  
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II. Methods 
 
A. Cells, antibodies, and plasmids.  Chinese hamster ovary (CHO-K1) cells lack HSV-1 
receptors and were grown in Ham’s F-12 medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin (58) at 37°C in 5% CO2. CHO-nectin1 is a cell line derived 
from CHO-K1 cells that expresses the HSV1 receptor nectin-1.  They were grown in Ham’s F-12 
medium supplemented with 10% FBS, 1% PS, and 250 µg/mL G418.  Trypsin-EDTA was used 
to detach these adherent cells.  The antibodies used include anti-HSV1 gD polyclonal antibody 
(PAb) R7 (33) anti-HSV1 gD 340-356 PAb (20), anti-EBV gB monoclonal antibody (MAb) 
CL55 (73)  anti-EBV gB PAb  (8), anti-hemagglutinin (HA) tag MAb 12CA5 (53), anti-FLAG 
M2 MAb (Sigma F9291), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG PAb 
(Pierce), and HRP-conjugated goat anti-rabbit IgG PAb HRP (Pierce).  HRP-conjugated 
streptavidin (Pierce) was used to detect biotin. Wildtype HSV glycoproteins were expressed using 
the pCAGGS vector (54). HSV1 gD-BirA, gD-AP, gD-APm EBV gB wildtype (24), EBV gB767 
(24), EBV gB816 (24), gB-BirA, gB-AP, gB-APm were expressed using the pSG5 vector 
(Agilent). For the syncytium formation assay the following plasmids were used: pPEP98 
(pCAGGS-HSV1 gB), pPEP99 (pCAGGS-HSV1 gD), pPEP100 (pCAGGS-HSV1 gH), and 
pPEP101 (pCAGGS-HSV1 gL). 
 
B. Transfection.  CHO-K1 cells were transfected in Opti-MEM (Gibco) medium using 
Lipofectamine 2000 (Invitrogen) according to the manufactures directions. Cells were grown in a 
24 well dish overnight and transfected with various combinations of expression vectors in Opti-
MEM for 3-5 hours. The transfection mixture was removed and the cells supplemented with Ham 
F-12 media for an overnight incubation at 37°C. 
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C. Western blot for total cell protein expression. CHO-K1 cells were transfected as described 
above. After an overnight incubation, cells were rinsed with PBS+ (phosphate-buffered saline 
containing 0.5 mM Mg2+, 0.9 mM Ca2+), detached with trypsin-EDTA and lysed using a RIPA 
buffer (radioimmunoprecipitation assay buffer: 1% NaDOC, 1% TX100, 0.1% SDS, 10 mM Tris-
Cl pH 7.4) with a mammalian protease inhibitor cocktail (M250, Amresco). Cell lysates were 
centrifuged at 14,000 g at 4°C for 5 minutes. The supernatants were collected, added to sample 
buffer with sodium dodecyl sulphate (SDS) and 2-mercaptoethanol, and boiled for 5 min.  
Samples were loaded on a 12% precast polyacrylamide gel (Bio-Rad) and separated by SDS-
PAGE.  
Proteins were transferred to 0.2 µm nitrocellulose membrane (Bio-Rad) at 150V for 1.5 
h. Blots were blocked with 5% dry milk for 30 minutes at room temperature (RT) or overnight at 
4°C. Blots were then incubated for 2h at RT with anti-HSV1 gD PAb peptide 340-356 antibody 
or anti-EBV gB PAb antibody diluted in PBS with 0.3% tween (PBS-T) and 5% milk. Blots were 
washed three times (5 minutes/wash) with PBS-T and goat anti-rabbit-HRP was added at a 
1:7,000 dilution in PBS-T with 5% milk for 1 hour, rocking at RT. After three PBS-T washes, the 
membranes were developed using enhanced chemiluminescence (ECL) substrate (Pierce) and 
detected with an HD2 imager (ProteinSimple). 
 
D. Cell-based enzyme-linked immunosorbent assay (cELISA).  To determine the protein 
expression on the surface of the cells. CHO-K1 cells were seeded (6 x 104 cells/well) in a 96-well 
plate and triplicate wells were transfected with 110 ng/well of DNA using 0.35 µL Lipofectamine 
2000/well (50 µL/well, total volume). The cells were incubated overnight at 37°C. The wells 
were blocked for 30 minutes at RT with PBS-BSA (PBS+ with 3% [wt/vol] bovine serum 
albumin).  Cells were incubated with R7 diluted 1:2,500 or CL55 diluted 1:10,000 in PBS-BSA 
on ice for 1 hour. The wells were rinsed three times with PBS+ and fixed in PBS+ with 2% 
formaldehyde and 0.2% glutaraldehyde. Cells were rinsed and incubated with goat anti-rabbit-
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HRP at 1:5,000 dilution or goat anti-mouse-HRP at 1:2,000 dilution for 1 hour at RT. Expression 
was determined by adding TMB microwell peroxidase substrate (Fisher) and measuring the 
absorbance at 670 nm on Biotek Cytation 3 Cell Imaging Multi-Mode Reader.  
 
E. Western blot for proximity biotinylation.  CHO-K1 cells seeded overnight in a 24 well plate 
(3 x 105 cells/well) were transfected as described above. After the overnight transfection, the cells 
were pulsed with 20 µM biotin at 37°C. Cells lysates were collected and subjected to SDS-
PAGE, as described above, using duplicate gels.  Samples were transferred to nitrocellulose as 
above and membranes were blocked with PBS with 1% BSA for 30 minutes at RT or overnight at 
4°C.  BSA was used to block the membranes because milk inhibits the biotin-streptavidin 
interaction. One membrane was incubated with streptavidin-HRP in PBS-T with 1% BSA for 1h 
and washed three times with PBS-T. The duplicate membrane was incubated for 2 hours at RT 
with either EBV gB PAb (diluted 1: 1,000 in PBS-T with 1% BSA) or 12CA5 (diluted 1: 2,000) 
in PBS-T with 1% BSA) to detect the HA-tagged AP constructs.  This membrane was washed 
and incubated with either goat anti-rabbit-HRP (1:10,000 dilution) or goat anti-mouse-HRP 
(1:7,000 dilution) in PBS-T with 1% BSA.  Both blots were developed using ECL as described 
above.  Then the duplicate blot was stripped using two 7 minute washes in a mild stripping buffer 
(15g glycine, 1g SDS, 10 mLTween-20 per liter adjusted to pH 2.2) followed by two 10 minute 
rinses in PBS and two 5 minutes rinses in Tris-buffered saline with 0.1 % Tween-20.  Signal loss 
was confirmed by imaging the blot using ECL.  This blot then was re-probed for 2 hours at RT 
using either anti-gD 340-356 PAb (diluted 1: 2,000 in PBS-T with 1% BSA) or anti-FLAG MAb 
(diluted 1: 7,000 in PBS-T with 1% BSA) to detect the FLAG-tagged BirA constructs. The blot 
then was washed, incubated with goat anti-mouse-HRP and developed as above. 
 
F. Depletion of biotin from medium.  Ham’s F12 supplemented with 10% FBS and 1%PS was 
depleted of free biotin by adding of 50 µg/mL of streptavidin (New England Biolabs 721).  CHO-
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K1 cells were transfected as described above, but the transfection mix was removed after 3-5 
hours and biotin-depleted media was added for the overnight incubation.  
 
G. Proximity biotinylation with immunoprecipitation.  CHO-K1 cells were seeded in a 12 
well plate (6 x 105 cells/well) and transfected as described with 440 ng of DNA/construct (880 
ng/well). After an overnight incubation, the cells were pulsed with 20 µM biotin for 5 minutes at 
37°C and cell lysates were collected as above using 400 µL/well of RIPA buffer.  The lysates 
were split, with 75 µL of each lysate reserved for immunoprecipitation (IP) (36). The rest of the 
cell lysates were analyzed by SDS-PAGE and western blot as described above.  
 To IP the AP constructs, 5µL of 12CA5 MAb was added to 75µL of lysates for 2h at 4°C 
on a rotator.  15µL of a 50% protein A/G+ bead slurry (Santa Cruz Biotechnology) was added for 
1h at 4°C on the rotator. After pelleting at 14,000 rpm for 1 minute at 4°C, the beads were 
washed with 1 mL RIPA buffer 5 times, with 30 seconds of centrifugation at 4°C after each wash. 
SDS-sample buffer at 2X with 2-mercaptoethanol was added to each pellet of beads. The samples 
were boiled for 5 minutes and centrifuged at 14,000g for 1 minute. The IP samples were 
separated by SDS-PAGE, transferred to nitrocellulose, and probed with streptavidin-HRP as 
described above.  
 
H. Competition proximity biotinylation assay. CHO-K1 cells seeded overnight in a 24 well 
plate (3 x 105 cells/well) were transfected with 450 ng/µL DNA per well, including 100 ng per 
AP- or BirA-linked construct and 250 per competitor construct. Cells were transfected in Opti-
MEM (Gibco) medium using Lipofectamine 2000 (Invitrogen) according to the manufactures 
directions. After 3-5 hours, the transfection mixture was removed and the cells were 
supplemented with Ham’s F-12 media at 37°C. After an overnight incubation, the cells were 
pulsed with 20 µM biotin at 37°C for 5 minutes. Cells lysates were collected and subjected to 
SDS-PAGE, as described above, using duplicate gels. The western blots were performed as 
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described above, with one blot probed using streptavidin-HRP and the other blot probed with 
anti-HA antibody and then re-probed with anti-FLAG antibody.  
 
I. Competition assay with gH. CHO-K1 cells seeded overnight in a 12 well plate (6 x 105 
cells/well) were transfected with 880 ng DNA per well (340 ng per construct, 100 ng HSV1 gH, 
100 ng HSV1 gL), as described above. After an overnight incubation, the cells were pulsed with 
20 µM biotin at 37°C for 5 minutes. Western blots were performed using cell lysates as described 
above, with one blot probed using streptavidin-HRP and another probed with anti-HA antibody 
followed by stripping and reprobing using anti-FLAG antibody. 
 
J. Syncytium formation assay. CHO-nectin1 cells were seeded (6 x 105 cells/well) overnight in 
24-well plates and then transfected with plasmids encoding HSV1 gB (pPEP98), gH (pPEP100), 
gL (pPEP101), and either gD (pPEP99), gD-BirA or gD-APm.  Each well received 900 ng DNA 
total, including 300 ng gB plasmid and 200 ng for each of the rest of the plasmids.  The cells were 
transfected in Opti-Mem (Gibco) medium for 3-5 hours using Lipofectamine 2000 (Invitrogen) 
according to the manufactures directions. The transfection mixture was replaced with Ham F-12 
supplemented with 10% FBS and PS and cells were incubated overnight at 37°C. Cells were 
fixed with methanol, stained with Giemsa (GibcoBRL), rinsed with water, and scored for 
syncytium formation by microscopy. 
 
K. Densitometry. To quantify the western blot bands the backgrounds of the blot were subtracted 
from the band. Densitometry values were determined using AlphaView Software from the 
FluorChem HD2 imager from ProteinSimple.  Values are provided under each blot.  
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III. Results 
 
A. Positive and negative ProB controls.  HSV and EBV entry glycoproproteins form multimers 
and thus detection of proximity between monomers of a glycoprotein can be used a positive 
control for the ProB assay.  The entry glycoproteins of EBV cannot be substituted for those of 
HSV and vice versa. Since glycoproteins from the two viruses do not functionally interact, they 
are not expected to physically interact, and thus they provide a negative control for the ProB 
assay. HSV1 gB and EBV gB share 29% identity and 43% similarity (7). Although the crystal 
structures of HSV1 and EBV gB demonstrate a common fold for these homologous proteins, their 
extensive sequence variations should preclude interaction of gB with heterotypic viral 
glycoproteins (7, 29). EBV does not utilize a glycoprotein gD. When EBV enters B cells, it uses 
gp42; however, gp42 is not required for entry into epithelial cells. There is no functional reason 
that EBV gB should interact with HSV1 gD. 
To validate ProB as a viable method to detect interactions between the HSV1 
glycoproteins necessary for entry, ProB constructs were cloned for HSV1gD and EBV gB.  The 
cytoplasmic tails of these proteins were linked to either biotin ligase (BirA) or its target peptide 
(AP or APm) (Fig. 3). APm is a 3 amino acid deletion, removing a tryptophan, histidine, glutamic 
acid from the original AP, shown to reduce background signal since it has a lower affinity for 
BirA (21). The BirA-linked constructs have a FLAG epitope tag, and AP- or APm-linked 
constructs have a hemagglutinin (HA) epitope tag.  
 
B. Expression of HSV1 and EBV constructs.  To determine if HSV1 gD constructs were 
expressed, plasmids encoding the constructs were transfected into CHO-K1 cells, and proteins 
from total cell lysates were analyzed by western blot (Fig. 4A). The wildtype HSV1 gD, gD-AP, 
and gD-APm migrated to 50 kDa, while gD-BirA migrated to 75 kDa (Fig. 4A). The proteins 
were detected with a polyclonal antibody serum specific for HSV1 gD. HSV1 gD-BirA was  
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Figure 3. Proximity biotinylation constructs. Schematic representation of HSV1 gD (A) and 
EBV gB (B) constructs linked with the biotin ligase BirA or the target peptides AP and APm.  
The BirA, AP, and APm were added to the cytoplasmic tails of the glycoproteins.  The dark blue 
and green boxes represent the transmembrane domains.  BirA-linked constructs include a C-
terminal FLAG epitope.  AP- and APm-linked constructs include a C-terminal HA tag. HSV gD-
BirA is expected to migrate to 75 kDa while HSV gD-AP and –APm are expected to migrate to 
50 kDa. EBV gB-BirA is expected to migrate to 200 kDa, and EBV gB-AP and –APm are 
expected to migrate to 140 kDa.  
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Figure 4. Expression of HSV1 constructs. (A) Western blot of HSV1 gD constructs.  Total cell 
lysates of CHO-K1 cells transfected with the gD constructs or empty vector were analyzed by SDS-
PAGE.  Proteins were transferred to nitrocellulose and probed using a polyclonal antibody serum 
specific for HSV1 gD.  Size markers in kDa are indicated on the left.  Densitometry values for the 
bands (~75 kDa for lane 2, ~50 kDa doublet for lanes 3-5) are below the blot. (B) CELISA of HSV1 
gD constructs. CHO-K1 cells were transfected with the gD constructs or empty vector and probed for 
cell surface expression of gD using a polyclonal antibody serum.  HRP-conjugated secondary 
antibody was added followed by substrate.  Absorbance at 670 nm was recorded as a measure of 
expression. 
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expressed at lower levels than wildtype gD. Cell surface expression of these gD proteins in CHO-
K1 cells was determined by cELISA (Cell-based Enzyme-Linked Immunosorbent Assay) using a 
gD polyclonal antibody (Fig. 4B). All the HSV1 gD constructs were present on the cell surface, 
suggesting that they were properly processed. gD-BirA was expressed on the cell surface at near 
wild-type levels, whereas gD-AP and gD-APm were present on the surface at somewhat lower 
levels.  
 The expression of the EBV gB constructs also was detected by western blotting of 
transfected CHO-K1 cell lysates (Fig. 5A) and cELISA of transfected CHO-K1 cells (Fig. 5B). 
Wild-type EBV gB is known to be poorly expressed at the cell surface, so two gB mutants 
(gB767 and gB816) that were previously shown express at higher levels on the cell surface were 
included as controls (24). gB767 and gB816 have cytoplasmic tail truncations that remove 
putative endocytosis motifs.  As expected, EBV gB-BirA migrated to 200 kDa, wildtype gB, gB-
AP, and gB-APm migrated to 140 kDa, and the truncated gB767 and gB816 migrated more 
rapidly (Fig. 5A). The gB ProB constructs were expressed at near wild-type levels in the cell 
lysates whereas the truncation mutants were expressed at lower levels.  As previously reported 
(24), wild-type gB expression on the surface was barely detectable (Fig. 5B).  The ProB 
constructs were also poorly expressed at similar levels on the cell surface.  As expected, the gB 
truncation mutants were expressed at higher levels on the cell surface.  The increase in surface 
expression for these mutants without a concurrent increase in total cell expression is consistent 
with previous reports (24).  Surface expression of the ProB mutants at near wild-type levels 
suggests that the proteins are properly processed. 
 
C. Initial ProB trial.  In the initial trial of ProB, CHO-K1 cells were transfected with 
combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector. Cells were 
pulsed with 20 µM biotin for 15 minutes and lysed. Cell lysates were analyzed by western blots. 
The levels of protein biotinylation were detected using streptavidin-HRP (Fig.6A).  
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  Figure 5. Expression of EBV constructs. (A) Western blot of EBV gB constructs.  Total cell 
lysates of CHO-K1 cells transfected with gB constructs or empty vector were analyzed by SDS-
PAGE. gB767 and gB816 are mutant forms of gB that were previously shown to be expressed at 
high levels on the cell surface.  Proteins were transferred to nitrocellulose and probed with a 
polyclonal antibody serum specific for EBV gB.  Size markers in kDa are indicated on the left. 
Densitometry values for the bands are below the blot. (B) CELISA of EBV gB constructs. CHO-
K1 cells were transfected with the gB constructs or empty vector and probed for cell surface 
expression of gB using a polyclonal antibody serum.  HRP-conjugated secondary antibody was 
added followed by substrate.  Absorbance at 670 nm was recorded as a measure of expression. 
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Coexpression of the homotypic pair HSV1 gD-BirA and HSV1 gD-APm resulted in strong 
biotinylation of the gD-APm target (~60 kDa, lane 3).  Coexpression of the homotypic pair EBV 
gB-BirA and EBV gB-APm also resulted in strong biotinylation of the gB-APm target (~140 
kDa, lane 8). Thus, proximity was detected in the positive controls. Results were similar whether 
the AP or APm constructs were used (data not shown).  APm is shown instead of AP because it 
has a reported lower affinity for BirA and resulted a reduction in non-specific bands (data not 
shown).   
 Unexpectedly, coexpression of the heterotypic pairings also resulted in biotinylation of 
the APm targets. Coexpression of HSV1 gD-BirA with EBV gB-APm resulted in biotinylation of 
gB-APm (~140 kDa, lane 4); however, the biotinylation was weaker than that observed for 
homotypic gB-BirA and gB-APm expression (lane 8). The other heterotypic combination (EBV 
gB-BirA and HSV1 gD-APm) also showed a weak biotinylation of the gD-APm (~60 kDa, lane 
9). The band migrating at ~60 kDa in lanes 4 and 8 is likely a degradation product of biotinylated 
EBV gB-APm since it is only present in gB-APm containing samples.  
gD-BirA, gD-APm, and wildtype gD expression was detected with a polyclonal antibody 
specific for peptide 340-356 of HSV1 gD. Both the enzyme and the substrate gD constructs were 
expressed but HSV1 gD-APm is expressed at a higher level compared to HSV1 gD-BirA (Fig. 
6C). Expression of EBV gB-BirA, APm, and wildtype was detected with a polyclonal antibody 
specific for EBV gB (Fig. 6B). Expression of both EBV gB-BirA and gB-APm is detected, 
however EBV gB-BirA expression in the last two lanes is weak. Interpretation of the heterotypic 
interaction between gB-BirA and gD-APm (lane 9) is complication by the poor detection of the 
gB-BirA expression. Subsequent experiments determined that the antibody for EBV gB does not 
detect gB as well as the antibody used for HSV1 gD, which could explain the lack of detection of 
the EBV gB glycoproteins on the cell surface. To try to reduce the signal for the heterotypic 
interaction, the exposure to biotin and amount of DNA transfected was reduced.  
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Figure 6. Initial trial of proximity biotinylation. CHO-K1 cells were transfected overnight 
with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector.  Each 
sample was transfected with 660 ng DNA total, comprising 220 ng per construct.  Cells were 
pulsed with 20 µM biotin for 15 min and then lysed.  Cell lysates were analyzed by SDS-PAGE 
and proteins were transferred to nitrocellulose.  Duplicate blots were generated and size markers 
in kDa are indicated on the left. (A) Biotinylated proteins were detected by probing with 
streptavidin-HRP.  The arrowhead denotes biotinylated EBV gB and the asterisk denotes a 
doublet band of biotinylated HSV1 gD.  (B) EBV gB expression was detected by probing a 
duplicate blot with polyclonal serum.  (C) The blot from B was stripped and reprobed with 
polyclonal serum to detect HSV1 gD expression. Densitometry values for the bands of interest 
are below each blot.  For A and C, the upper value represents the larger molecular weight species. 
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D. ProB assay optimization with lower amounts of DNA, shorter biotin exposure.  Since the 
level of biotinylation was greater than expected in the heterotypic combinations, the amount of  
DNA transfected was reduced and the cell exposure to biotin was shortened (Fig. 7). The amount 
of DNA was reduced more than 2-fold from the previous experiment (to 300 ng DNA per well). 
Cells were exposed to the same concentration of biotin (20 µM), but for 5 minutes rather than 15 
minutes. The HSV1 gD homotypic combination showed a strong biotinylation signal (lane 3, ~60 
kDa), as did the EBV gB homotypic combination (lane 7, ~140 kDa). The heterotypic pairing of 
HSV1 gD-BirA and EBV gB-APm resulted in biotinylation of gB-APm (lane 4, ~140 kDa), but 
quantification of this band is difficult due to the presence of a background band in all of the lanes 
that migrates at the same molecular weight. This cellular biotinylated protein was present in the 
previous experiment (Fig. 6), but at lower levels compared to gB.  Reducing the amount of DNA 
transfected complicated interpretation of the blot because the ratio of expression of gB to the 
background band was reduced.  A heterotypic interaction between EBV gB-BirA and HSV1 gD-
APm is apparent (lane 8, ~60 kDa). A degradation product of biotinylated gB-APm is apparent 
again in lanes 4 and 8 at ~60 kDa. The dots in lane 3 are an artifact, most likely streptavidin-HRP 
precipitate that adhered to the blot. The gD and gB constructs EBV were expressed at levels 
similar to the previous western blots (data not shown). The EBV polyclonal antibody still was not 
detecting gB levels well. To better detect gB and gD constructs, a new set of antibodies was used 
that allows direct comparison of the levels of BirA enzyme and APm substrate.   
 
E. ProB assay optimization using the FLAG and HA epitopes. Since the EBV gB antibody did 
not detect EBV gB well, antibodies specific for the FLAG and HA epitopes on the proteins were 
tested. Using the epitope tags to detect the proteins also allowed better comparison of protein 
levels, since both of the BirA enzymes constructs have FLAG tags, and both of the APm substrate 
constructs have HA tags. Constructs were co-transfected in this experiment to determine the 
expected expression levels of the glycoproteins when co-transfected in future experiments (Fig. 
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Figure 7. Proximity biotinylation trial with less DNA and shorter biotin exposure. CHO-K1 
cells were transfected overnight with combinations of HSV1 gD constructs, EBV gB constructs, 
and/or empty vector.  Each sample was transfected with 300 ng DNA total, comprising 100 ng 
per construct.  Cells were pulsed with 20 µM biotin for 5 min and then lysed.  Cell lysates were 
analyzed by SDS-PAGE and proteins were transferred to nitrocellulose. Biotinylated proteins 
were detected by probing with streptavidin-HRP. The two halves of the blot are from the same 
exposure. Size markers in kDa are indicated on the left. The arrowhead denotes biotinylated EBV 
gB and the asterisk denotes a biotinylated HSV1 gD. Densitometry values for the bands of 
interest are below each blot.  The upper value represents the larger molecular weight species. 
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Figure 8. Detection of constructs expression using HA and FLAG tags. Western blot of APm 
and  BirA constructs.  Total cell lysates of CHO-K1 cells transfected with HSV1 gD constructs, 
EBV gB constructs, and/or empty vector were analyzed by SDS-PAGE. Proteins were transferred 
to nitrocellulose and probed with a monoclonal antibodies specific for the HA tag (A) or the 
FLAG tag (B). Size markers in kDa are indicated on the left.  The arrowhead denotes EBV gB 
and the asterisks denote HSV1 gD. Densitometry values for the bands of interest are below each 
blot.  For A, the upper value represents the larger molecular weight species. 
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 8). EBV gB-APm was detected at ~140 kDa and HSV1 gD-APm was detected at ~60 kDa (Fig. 
8A). EBV gB-BirA was detected at ~150 kDa and HSV1 gD-BirA was detected at ~75 kDa (Fig. 
8B). Stronger signals were perceived with the anti-FLAG monoclonal antibody and the anti-HA 
monoclonal antibody compared to the EBV gB antibody seen in previous blots.  Cellular proteins 
that react with the anti-HA antibody are present in all lanes and migrate to the same molecular 
weight as gD as well as at ~75 kDa.  
 A ProB assay was performed as previously, using 375 ng DNA per well and the HA or 
FLAG epitopes to assess protein expression levels (Fig. 9). Biotinylation is apparent in the 
homotypic combinations for both HSV1 gD (lane 2) and EBV gB (lane 6). The heterotypic 
combinations have weaker but detectable biotinylation signals (lanes 3 and 7). All of the APm 
and BirA constructs were expressed, with the gB constructs again at higher levels than the gD 
constructs again (Fig. 9B, 9C). The detection of the enzyme and substrate with the HA and FLAG 
epitopes were useful for comparison of the enzyme levels (gB-BirA and gD-BirA) and substrate 
levels (gB-APm and gD-APm).  
 
F. ProB with depletion of free biotin. The cellular protein(s) that react with streptavidin-HRP 
and migrate to ~140 kDa obscure observation of biotinylated gB-APm. These bands may result 
from endogenous biotin being detected by the streptavidin-HRP. In attempt to decrease the 
presence of these background biotinylated species, two sets of ProB samples were compared.  
One set was treated as before (Fig. 10A) and for a second set, the media was depleted of free 
endogenous biotin by the addition of streptavidin (Fig. 10B).  For this second set, streptavidin 
was maintained in the media after transfection for the duration of the overnight incubation prior 
to the biotin pulse. CHO-K1 cells were transfected with 660 ng DNA per well total, including 220 
ng per construct. As seen previously, the homotypic combinations yield strong biotinylation 
signals (Fig. 10A, lanes 2 and 6). The heterotypic combination yields weaker biotinylation signals 
than the homotypic interactions (Fig. 10A, lanes 3 and 7). Depletion of the free biotin did not  
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Figure 9. Proximity biotinylation using HA and FLAG tags. CHO-K1 cells were transfected 
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector. 
Each sample was transfected with 300 ng DNA total, comprising 150 ng per construct. Cells were 
pulsed with 20 µM biotin for 5 min and then lysed.  Cell lysates were analyzed by SDS-PAGE 
and proteins were transferred to nitrocellulose. Size markers in kDa are indicated on the left. (A) 
Biotinylated proteins were detected by probing with streptavidin-HRP.  The arrowhead denotes 
biotinylated EBV gB and the asterisks denote a doublet band of biotinylated HSV1 gD.  (B) APm 
was detected by probing a duplicate blot with an antibody specific for the HA tag.  (C) The blot 
from B was stripped and reprobed with an antibody specific for the FLAG tag, detecting BirA 
expression. The arrowhead denotes EBV gB and the asterisks denote HSV1 gD. Densitometry 
values for the bands of interest are below each blot.  For A, the upper value represents the larger 
molecular weight species. 
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Figure 10. Proximity biotinylation after biotin-depletion of the medium. Duplicate sets of 
CHO-K1 cells were transfected with combinations of HSV1 gD constructs, EBV gB constructs, 
and/or empty vector.  Each sample was transfected with 660 ng DNA total, comprising 220 ng 
per construct.  One set of samples was treated as in Fig. 5 (A).  The medium for the other set (B) 
was supplemented with 50 µg/mL streptavidin to bind endogenous biotin.  After an overnight 
incubation, all cells were pulsed with 20 µM biotin for 5 min and then lysed.  Cell lysates were 
analyzed by SDS-PAGE and proteins were transferred to nitrocellulose.  Biotinylated proteins 
were detected by probing with streptavidin-HRP.  The arrowhead denotes biotinylated EBV gB 
and the asterisks denote a biotinylated HSV1 gD. Densitometry values for the bands of interest 
are below each blot.  The upper value represents the larger molecular weight species. 
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affect the results (Fig. 10B) and did not decrease the signal from the background cellular protein 
migrating at the same size as gB-APm. The biotinylated species is not impacted by depletion of 
the free biotin in the media. 
 
G. ProB with immunoprecipitation (36).  To reduce the impact of the non-specific bands in the 
western blots, the APm constructs were immunoprecipitated prior to loading the gels. The ProB 
was performed and cell lysates were collected as previously.  Then the APm constructs were 
immunoprecipitated from the lysates using an antibody specific for the HA tag and beads 
covalently-conjugated to protein A/G. Samples were reordered on the gel for easier comparison 
of homotypic and heterotypic combinations.  The IP eliminated the biotinylated cellular species 
that previously obscured the gB-APm band.  As before, both homotypic and heterotypic 
interactions are apparent.  Biotinylation of gD-APm is similar when it is coexpressed with either 
homotypic gD-BirA or heterotypic gB-BirA (Fig. 11A, lanes 1 and 2).  Given than gB-BirA is 
expressed at a greater level than gD-BirA (Fig. 11C), this may indicate that biotinylation of the 
homotypic combination is more specific than the heterotypic combination.  Biotinylation of gB-
APm is greater when it is coexpressed with the homotypic gB-BirA rather than the heterotypic 
gD-BirA (Fig. 11A, lanes 4 and 5), however this results may be influenced by the fact that gD-
BirA is expressed at lower levels than gB-BirA (Fig. 11C). 
 
H. gD construct function in fusion. The HSV1 gD constructs tagged with BirA and APm were 
tested for their ability to mediate cell-cell fusion. CHO-nectin-1 cells were used since this cell 
type expresses nectin-1, a herpesvirus receptor expressed on neurons. CHO-nectin-1 cells 
transfected with wildtype HSV1 gB, gD, gH, and gL formed large syncytia (Fig. 12). When the 
fusion protein gB was excluded from the transfection, cells did not form syncytia. When cells 
were transfected with plasmids encoding gB, gH, gL and either gD-APm or gD-BirA, many large  
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Figure 11. Proximity biotinylation with immunoprecipitation. CHO-K1 cells were transfected 
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and/or empty vector.  
Each sample was transfected with 880 ng DNA total, comprising 440 ng per construct.  Cells 
were pulsed with 20 µM biotin for 5 min and then lysed.  Lysates were divided for 
immunoprecipitation (A) or direct loading onto the gel (B and C).  (A) The APm constructs were 
immunoprecipitated from the lysates using an antibody specific for the HA epitope tag and 
protein A/G beads.  Biotinylated proteins were detected by probing with streptavidin-HRP. (B) 
APm was detected by probing a duplicate blot with an antibody specific for the HA tag.  (C) The 
blot from B was stripped and reprobed with an antibody specific for the FLAG tag, detecting 
BirA expression. The arrowhead denotes EBV gB and the asterisks denote HSV1 gD. 
Densitometry values for the bands of interest are below each blot.  For A, the upper value 
represents the larger molecular weight species.  
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Figure 12. Syncytium formation with gD constructs BirA and APm.  CHO-nectin-1 cells 
were transfected with plasmids encoding HSV1 glycoproteins or gD constructs, and/or empty 
vector. The results shown are representative of 3 replicates. The images were taken 24h post 
transfection. Arrows indicate syncytia.  
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syncytia formed. The results indicated that gD-APm and gD-BirA are functional proteins, further 
supporting that they are properly folded in the cell. 
 
I. ProB competition assay.  To examine specificity of the ProB assay and address whether the 
affinity of BirA for APm contributes to the biotinylation signal, wildtype protein was added in 
attempt to outcompete the heterotypic interaction. If the interactions that yield biotinylation are 
driven by attractions between the glycoprotein ectodomains, excess wild-type protein should be 
able to compete for the binding and decrease the biotinylation signal.  In contrast, if the  
interactions that yield biotinylation are driven by an inherent attraction between BirA and APm, 
the addition of excess wildtype gD or gB should not affect the level of APm biotinylation. 
For the heterotypic gD-BirA and gB-APm combination, coexpression of wildtype EBV 
gB resulted in a slight reduction in gB-APm biotinylation (Fig. 13, lane 5 and 6).  This reduction 
suggested that the heterotypic gD-BirA interaction with gB-APm might result from interactions 
with the gB ectodomain rather than from an inherent affinity between BirA and APm, however 
this competition was not consistently detected.  When the heterotypic combination was reversed 
(gB-BirA coexpressed with gD-APm), coexpression of wildtype gD did not inhibit biotinylation 
(lanes 3 and 4).  Furthermore, the level of biotinylation for the homotypic gB-BirA and gB-APm 
combination was not affected by the addition of wildtype gB (lane 7 and 8).   The crystal 
structure of the gB ectodomain (29) demonstrates that the gB ectodomin trimerizes, so wildtype 
gB was expected to inhibit the interaction between gB-BirA and gB-APm.  The inability to detect 
competition by wild-type gB suggests that the inherent affinity between BirA and APm may 
contribute to gB-APm biotinylation.  The gD homotypic combination failed to show high levels 
of biotinylation (lanes 9 and 10).  This may be due to poor expression of gD-BirA. When the 
BirA blot was stripped and re-probed with the anti-gD polyclonal antibody, no gD-BirA was 
detected. It was expected to migrate to 75 kDa. Subsequent experiments failed to show clear 
competition when the wildtype protein was coexpressed with corresponding combinations. 
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J. ProB HSV1 gH/gL competition assay.  On the HSV1 virion, gB and gD exist in combination 
with gH/gL. To examine whether gH/gL influences the HSV1 gD-EBV gB interaction, HSV 
gH/gL was added to the ProB assay. This assay is an alteration of the competition assay above. 
Instead of using wildtype gD or gB to compete the interaction, HSV1 gH and gL were 
coexpressed with the BirA and APm constructs. In one experiment, coexpression of the gH/gL 
complex decreased biotinylation for the heterotypic combination of gB-BirA and gD-APm (Fig. 
14, lanes 3 and 4). In the same experiment, coexpression of gH/gL did not affect homotypic 
biotinylation of gD-APm by gD-BirA (lanes 1 and 2). The levels of APm biotinylation were 
similar with or without gH/gL coexpression. Expression of the BirA constructs was unable to be 
detected in that experiment and the results were not reproducible.  
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Figure 13. Competition proximity biotinylation assay. CHO-K1 cells were transfected 
overnight with combinations of HSV1 gD constructs, EBV gB constructs, and either empty 
vector or wildtype proteins.  Each sample was transfected with 450 ng DNA total, comprising 
100 ng per construct or 250 ng per competitor.  Cells were pulsed with 20 µM biotin for 5 min 
and then lysed.  Cell lysates were analyzed by SDS-PAGE and proteins were transferred to 
nitrocellulose. (A) Biotinylated proteins were detected by probing with streptavidin-HRP. (B) A 
blot detecting BirA expression using an antibody specific for the FLAG tag. (C) HSV1 gD 
expression using a polyclonal antibody serum specific for HSV1 gD. Size markers in kDa are 
indicated on the left. The arrowhead denotes biotinylated EBV gB and the asterisks denote a 
biotinylated HSV1 gD. Densitometry values for the bands of interest are below each blot.  For A, 
the upper value represents the larger molecular weight species.  
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Figure 14. Competition proximity biotinylation assay with HSV1 gH/gL. CHO-K1 cells were 
transfected overnight with combinations of HSV1 gD constructs, EBV gB constructs, and either 
empty vector or HSV1 gH/gL.  Each sample was transfected with 880 ng DNA total, comprising 
340 ng per construct or 100 ng for gH and gL.  Cells were pulsed with 20 µM biotin for 5 min 
and then lysed.  Cell lysates were analyzed by SDS-PAGE and proteins were transferred to 
nitrocellulose. (A) Biotinylated proteins were detected by probing with streptavidin-HRP. (B) A 
blot detecting APm expression using an antibody specific for the HA tag. Size markers in kDa are 
indicated on the left. The asterisk denotes a biotinylated HSV1 gD. Densitometry values for the 
bands of interest are below each blot.  For A, the upper value represents the larger molecular 
weight species.  
 
*	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 IV. Discussion 
 The HSV1 gD constructs with BirA and APm linked to the cytoplasmic tails were 
expressed, as demonstrated by western blot and CELISA (Fig. 4).  Total cell protein expression of 
gD-BirA expressed was reduced compared to wild-type gD, but cell surface expression was at 
wild-type levels, suggesting that the mature protein is properly folded. The double banding 
pattern apparent in the western blot for both wildtype and mutant gD constructs are likely due to 
different glycosylation of this glycoprotein. The syncytia assay confirms the proper folding of 
these gD ProB constructs, since they are functional in fusion (Fig. 12).  
 The EBV gB constructs with BirA and APm linked to the cytoplasmic tails also were 
expressed as detected by western blotting (Fig. 5). As seen previously, detection of wild-type 
EBV on the cell surface is difficult.  The gB ProB constructs were detected on the cell surface at 
the same low levels as wild-type gB.  The EBV gB tail mutants (EBV gB767 and gB816) that are 
known to be expressed at higher levels on the surface of the cell were detected at higher levels by 
cELISA. The tail mutants do not show higher levels of overall expression in the western blot, 
suggesting that these proteins localize preferentially to the cell surface.  The tail mutants lack 
internalization signals present in wildtype gB.  These results suggest that the gB-BirA and gB-
APm constructs exhibit wild-type levels of internalization. Overall, the gB constructs are 
expressed at similar levels to wild-type gB. 
 The initial ProB trial showed biotinylation in both homotypic combinations (Fig. 6). The 
gB homotypic biotinylation was greater than the HSV homotypic biotinylation. Both of the 
heterotypic combinations also demonstrated biotinylation. Since these transmembrane 
glycoproteins are tethered to a membrane, they are in close proximity with one another.  This 
proximity may facilitate random collisions that are sufficient to allow for the biotinylation of the 
AP tag without specific protein-protein binding.  Optimizations of the ProB assay conditions are 
required to differentiate between a specific versus random interaction.  
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 When the amount of DNA and the biotin exposure time were reduced, the homotypic 
interactions were harder to detect (Fig. 7). Since biotinylation was still seen, the shorter biotin 
exposure time was sufficient for biotinylation. The protein expression after transfection using 100 
ng per construct was too low for reliable detection in this ProB assay.  
 The HSV gD and EBV gB polyclonal antibodies did not detect the glycoproteins 
effectively. The ProB constructs were designed with FLAG and HA epitopes and antibodies 
specific for those tags gave enhanced detection of the proteins (Fig. 8).  In addition, use of these 
epitope tags allowed direct comparison of the levels of gB-BirA versus gD-BirA.  
 Using the epitope tags to compare enzyme levels during the ProB assay provided a 
clearer picture. The substrate constructs (APm) were expressed at similar levels, but the enzyme 
constructs (BirA) were not expressed at similar levels (Figs. 8, 9, 11). gD-BirA is expressed at a 
lower level than gB-BirA and this complicates the interpretation of the results. Specifically, 
comparing the gB homotypic interaction with the heterotypic interaction between gD-BirA and 
gB-APm is difficult, since gD-BirA is expressed at lower levels than gB-BirA.  The weaker 
biotinylation seen with the heterotypic combination (Fig.11) could result simply from the lower 
levels of enzyme expressed.  This result cannot be interpreted to indicate that the homotypic 
interaction is stronger than the heterotypic interaction. 
  A nonspecific band that migrates at the same molecular weight as gB-APm was apparent 
on many of the western blots probed with streptavidin-HRP. This signal is from endogenous 
biotinylated proteins, since it is present in samples that did not receive BirA. When the media was 
depleted of free biotin by the addition of streptavidin, the nonspecific bands remained, indicating 
that depleting endogenous biotin overnight was insufficient to eliminate endogenous biotinylation 
(Fig. 10). 
 To eliminate this confounding nonspecific band, an antibody specific for the HA tag on 
APm constructs was used to immunoprecipitate these proteins. The IP blot still shows a 
nonspecific band at a molecular weight similar to gD-APm, but the band that overlapped the gB-
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APm was successfully lost in the immunoprecipitation (Fig. 11). As seen in the previous ProB 
trials, both of the homotypic combinations showed strong biotinylation, however the heterotypic 
combinations also showed biotinylation.  Interpretation of the specificity of the interaction 
requires consideration of the expression levels of the constructs.  The gD-APm and gB-APm 
constructs are expressed at similar levels, so the effect of different APm concentrations in the 
samples is minimized.  In contrast, gB-BirA is expressed at greater levels than gD-BirA (up to 
two-fold greater in some cases).  Given that BirA is an enzyme, capable of biotinylating several 
APm substrates, difference in BirA construct expression levels may be amplified (Fig. 15). 
The homotypic combination of gD-BirA and gD-APm (Fig. 11, lane 1) results in 
biotinylation levels similar to the heterotypic combination of gB-BirA and gD-APm (Fig. 11, lane 
2).  Since gD-BirA is expressed at lower levels than gB-BirA, this result may indicate that this 
homotypic gD interaction is stronger than the heterotypic interaction (Fig. 15).  In contrast, 
although the homotypic combination of gB-BirA and gB-APm (Fig. 11, lane 4) results in over 
two-fold greater levels of biotinylation than the heterotypic combination of gD-BirA and gB-
APm (Fig. 11, lane 5), the lower expression of the gD-BirA may account for this difference.   
 The competition assay with HSV1 gH/gL showed that gH/gL may outcompete the 
heterotypic interaction between HSV1 gD-APm and EBV gB-BirA (Fig. 14). A slight decrease is 
seen in the heterotypic interaction with gH/gL compared to the heterotypic interaction without 
(lane 3 and 4). This decrease was difficult to reproduce and more experiments need to be 
performed to replicate these results.  
 
A. Proximity biotinylation potential.  ProB has been used previously to detect cytosolic protein 
interactions, however its use as a method to detect transmembrane protein interactions may be 
limited. The ProB assay was used successfully to study with the intracellular protein-protein 
interactions FKBP or FK506 and FKBP-rapamycin binding (FRB) protein, which is regulated by 
rapamycin (21). Transmembrane proteins have restricted mobility while in the membrane. This  
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  Figure 15. Depiction of the effect of enzyme concentration on biotinylation.  (A,B) 
Homotypic combinations.  (C, D) Heterotypic combinations.  (A and C) gD-BirA and gB-BirA 
catalyze similar levels of biotinylation when coexpressed with gD-APm, however gD-BirA is 
expressed at a lower level than gB-BirA.  This may suggest that gD-BirA interacts more 
frequently with the substrate gD-APm than does gB-BirA.  (B and D) gB-APm is biotinylated to 
a greater extent when coexpressed with homotypic gB-BirA rather than heterotypic gD-BirA, 
however gB-BirA is expressed at a higher level than gD-BirA.  This enhanced expression of gB-
BirA may contribute to its ability to biotinylate gB-APm to a greater degree.  
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may contribute to unexpected non-specific interactions between the HSV1 gD and EBV gB 
proteins.  
As discussed, the expression level of the BirA-linked construct is critical for 
interpretation of the data.  In addition, the functionality of the BirA enzyme linked to each 
construct may differ. ProB is ideal for proteins with flexibility in their structures or proteins that 
are able to function with an altered shape.  The spacing from the membrane of a BirA and APm 
pair may affect the frequency of biotinylation.  
ProB has the potential to be a useful method to study protein interactions due to the use 
of an enzyme-substrate pair instead of the use of a fluorophore. The target substrate is a small tag, 
which has a limited ability to affect the function of the protein whereas the BirA enzyme is about 
20 kDa.  The detection of the interaction is determined via western blot, making it easier to 
quantify than microscopy. The major advantage of ProB is the covalent linking of biotin to the 
AP tag, permanently tagging the protein.  
This thesis project was to establish and optimize a protocol for proximity biotinylation. 
The number of cells used, the antibody dilutions, the selection of antibodies, the amounts of 
DNA, biotin exposure, endogenous biotin depletion, and immunopreciptation conditions were 
optimized for this assay.  
 
B. Future work.  The interactions between the HSV1 glycoproteins are an active area of 
research. Further optimization of the ProB assay to reduce detection of nonspecific interaction 
may be possible.  
HSV1 gD and EBV gB were not expected to physically interact because EBV gB and 
HSV1 gB cannot functionally replace one another.  In addition, they have low sequence 
homology (~30%) and EBV does not encode a gD homolog.  These facts do not preclude the 
possibility that HSV1 gD and EBV gB interact in a specific but non-functional manner.  An 
alternative negative control could be used to optimize the ProB assay, such as the fusion 
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glycoprotein F from the paramyxovirus parainfluenza virus 5 (PIV5). F protein is a fusion protein 
on the surface that PIV5 that triggers membrane fusion. PIV5 F has no sequence homology to 
HSV1 proteins. This is reasonable negative control since it is a transmembrane protein that forms 
a trimer and thus could be used to examine both homotypic and heterotypic interactions. 
 The ProB competition assay results with wildtype EBV gB and HSV1 gD, as well as 
HSV1 gH/gL, should be repeated to determine if the results are reproducible. Examination of the 
interaction of HSV1 gH/gL with HSV1 gD and gB can be examined once the ProB specificity 
concerns are addressed. 
 BirA and APm interactions can also be visualized through fluorescent microscopy. The 
procedure is similar except the cells are not lysed but fixed and then stained with streptavidin 
conjugated to AlexaFluor 568 or another fluorescent molecule. The media depletion of biotin can 
reduce background biotin signal. Fluorescent microscopy analysis of the HSV1 gD and EBV gB 
constructs can be beneficial in characterizing if any nonspecific interactions are happening during 
processing in the endoplasmic reticulum instead of interacting on the cell surface. 
 
C. Other protein-protein interaction methods. Further development in protein interaction 
methods for herpesvirus proteins is necessary to characterize the interaction of the glycoproteins 
for entry. 
 Proximity utilizing biotinylation and mass spectrometry (PUB-MS) employs the same 
enzyme- substrate method using biotin ligase (BirA) and biotin-acceptor tag (AP). The 
interactions can be monitored by western or mass spectrometry. The researchers used a strong 
CMV promoter or a weaker MoMuLV enhancer to have AP in excess over BirA (40). Cloning 
these herpesvirus proteins into plasmids with different promoters may help optimize the positive 
and negative controls for the ProB assay.  
 Another method related to ProB is called ID-PRIME. This assay takes advantage of the 
enzyme E. coli lipoic acid ligase, which catalyzes the covalent ligation of a coumarin fluorophore 
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onto a peptide recognition sequence, LAP1 (62). Only when the proteins labeled with either the 
ligase or LAP1 interact is the LAP1 labeled with coumarin, a blue fluorophore. Coumarin 
labeling in the absence of the interaction is low. The enzyme was created in such a way that when 
the interaction is present the labeling is maximally fast, but when the interaction is not present the 
labeling is undetectably slow (62). The issue with this method is that some endogenous proteins  
are lipoylated, arising to the same problem as endogenous biotinylation with ProB (62). Other 
protein-protein interactions will not work for low affinity, transient interactions that occur with 
the entry glycoproteins.  
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V. Appendix 
 
Cloning BirA and APm onto the cytoplasmic tails of HSV1 gB, HSV1 gH, and PIV5 F. The 
cloning strategy was designed using four-primer PCR.  In this method, one primer pair is used to 
amplify the 5’ fragment of a construct and a second primer pair is used to amplify the 3’ fragment 
of a construct.  The 3’ primer of the first PCR and the 5’ primer of the second PCR are designed 
to have sequence overlap.  Thus, the product of the first PCR will base-pair with the product of 
the second PCR.  The 5’ primer of the first PCR and the 3’ primer of the second PCR can then be 
used to amplify the full-length construct.  Incorporation of restriction sites into the 5’ and 3’ 
primer used in the second round of PCR allows the fragment to be ligated into an expression 
vector.  A benefit to the four-primer PCR approach is that the two halves of the construct can be 
joined precisely, without any additional residues being added, such as those encoded by 
restriction site sequences.  
The primers were designed so that the BirA and APm fragments would be amplified 
without any glycoprotein sequence included, so that these PCR products could be use to add BirA 
or APm to  any of the glycoproteins. The 3’ primer for amplifying BirA included a FLAG epitope 
and the 3’ primer for amplifying APm included an HA epitope.   
Primers also were designed to clone each glycoprotein in combination with BirA and 
APm.  The 5’ primer used to amplify the glycoproteins was the same, regardless of whether the 
BirA or APm was to be added.  The 3’ primers included sequence from the glycoprotein and 
either BirA or APm.  This 3’ primer is the primer that includes the sequence overlap required for 
this four-primer PCR method. Plasmids pPEP100 (pCAGGs-gH), pSG5-EBVgB, and pCAGGs-
W3AF (PIV5 F protein), and pECFP-N1-BirA-neurexin were used as templates for 
amplifications.  The sequence of APm is short enough to be entirely encoded in the primer. 
To amplify the 5’ fragment of the HSV1 gH-BirA construct, a 5’ primer (rSC22) and a 3’ 
primer (rSC25b) amplified gH with a 3’ end complimentary to BirA. To amplify the 5’fragment 
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gH-APm, the same 5’ primer was used in combination with a 3’ primer  (PCR28b) to amplify gH 
with a 3’ end complementary to APm.  
To amplify HSV1 gB-BirA, the 5’ primer rSC89 was used in addition to the 3’ primer 
rSC25b. To amplify HSV1 gB-APm, the 5’ primer rSC18 was used with the 3’ primer rSC28b.  
 To amplify the 5’ fragments of the PIV5 F constructs, a 5’primer (rSC90) was used in 
combination with a 3’ primer including F sequence and either BirA (rSC25c) or APm . (rSC28c) 
sequence.  
To amplify the 3’ BirA fragment, the 5’ primer (rSC63) was used in combination with a 
3’ primer with the restriction enzyme site for BglII (rSC25b) or EcoRI (rSC25c). To amplify the 
3’ APm fragment, the 5’ primer (rSC64) was used in combination with a 3’ primer with the 
restriction enzyme site for BglII (rSC28b) or EcoRI (rSC28c).   
The full-length constructs were amplified using the products of these PCRs and the 
appropriate primer combinations, from the primers listed above.  The primers used in this cloning 
had varied length, by necessity, and were used in more than one PCR, thus optimization of the 
PCR conditions was required.  The viral glycoproteins have are GC-rich and thus optimization 
was extensive, including temperature gradient PCR to determine optimal annealing temperatures 
and the use of different polymerases.  
The amplified full-length constructs were digested and ligated into the vector pSG5.  This 
vector has only three restriction sites in the multiple cloning site, so directional cloning was not 
possible.  The ligations were transformed into competent cells and the proper orientation of the 
fragment was confirmed either by diagnostic restriction digest of DNA isolated from a 
transformant by miniprep or by PCR amplification directly from an isolated colony. 
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Table 1. Primer name and corresponding sequences for HSV1 gB, gH, and PIV5 F protein.  
 
Primer 
name Gene/Plasmid Sequence 5’ to 3’ 
rSC18 5’ EcoRI-HSV1 gB 
CGGAATTCACCATGCACCAGGGCGCCCCCTC 
 
rSC22 5’ BglII-HSV1 gB 
CGAGATCTACCATGGGGAATGGTTTATGGTT 
 
rSC25b RC3’ BirA-FLAG-BglII 
GCAGATCTCTACTTGTCGTCGTCGTCCTTGTAGTCACCTCCTTT
TTCTGCACTACGCAGG 
rSC25c RC3’ BirA-FLAG-EcoRI 
GCGAATTCTACTTGTCGTCGTCGTCCTTGTAGTCACCTCCTTTT
TCTGCACTACGCAGGG 
 
rSC28b RC3’ APmut-FLAG-BglII 
GCAGATCTCTAGAACTCGCCCTCGATCTTCTGGGCCTCGAAG
ATATCGTTCAGGCCGCCT 
rSC28c RC3’ APmut-HA-EcoRI 
GCGAATTCTAGAACTCGCCCTCGATCTTCTGGGCCTCGAAGA
TATCGTTCAGGCCGCCTC 
rSC57 RC3’ HSV gB-BirA 
GGCACGGTGTTATCCTTCATCAGGTCGTCCTCGTCGGCGT 
 
rSC58 RC3’ HSV gB-AP 
TCGGGCACGTCGTAGGGGTACAGGTCGTCCTCGTCGGCGT 
 
rSC61 RC3’ HSV gH-BirA 
GGCACGGTGTTATCCTTCATTTCGCGTCTCCAAAAAAACG 
 
rSC62 RC3’ HSV gH-AP 
TCGGGCACGTCGTAGGGGTATTCGCGTCTCCAAAAAAACG 
 
rSC63 5’ BirA ATGAAGGATAACACCGTGCC 
rSC64 5’ HA-AP TACCCCTACGACGTGCCCGACTACGCCAGCCTGGGAGGCGGCCTGAACGATA 
rSC89 5’ EcoRI-KOS gB 
GCGGAATTCACCATGCACCAGGGTGCACCCTCGT 
 
rSC90 5’ EcoRI- PIV5 F 
GCGGAATTCACCATGGGTACTATAATTCAATTTC 
 
rSC91 RC3’ PIV5 F-BirA 
GGCACGGTGTTATCCTTCATTTTATGATAAACAAAATTCT 
 
rSC92 RC3’ PIV5 F-AP 
TCGGGCACGTCGTAGGGGTATTTATGATAAACAAAATTCT 
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Table 2. Optimal PCR conditions to amplify 5’ and 3’ fragments  
 
 Cycle 30X  
Fragment Enzyme Template Primers Initial Den. Denature Anneal. Extension 
Final 
Ext. 
PCR1d 
(5’ BirA, 
BglII) 
pg 2-3 
Vent 
pECFP-
N1-BirA-
neurexin 
rSC63, 
rSC25b 
98C, 
60s 98C, 30s 
66.5C, 
60s 72C, 2:40 
72C, 5 
min 
PCR5 
(5’ gH, 
BirA) 
pg 1 
Vent 
pEP100 
(pCAGGS-
gH) 
rSC22, 
rSC61 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR6 
(5’ gH, 
APm) 
pg 1 
Vent 
pEP100 
(pCAGGS-
gH) 
rSC22, 
rSC62 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR3 
(5’ AP, 
BglII) 
pg 1 
Vent N/A rSC64, rSC28b 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR9 
(5’ PIV5, 
BirA) 
pg 1 
Vent pCAGGS-W3AF 
rSC90, 
rSC91 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR2e 
(5’ BirA, 
BglII) 
pg 3 
Vent 
pECFP-
N1-BirA-
neurexin 
rSC63, 
rSC25b 
98C, 
60s 98C, 30s 47C, 60s 72C, 60s 
72C, 5 
min 
PCR10 
(5’ PIV5, 
APm) 
pg 1 
Vent pCAGGS- W3AF 
rSC90, 
rSC92 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR4 
(5’ AP, 
EcoRI) 
pg 1 
Vent N/A rSC64, rSC28c 
98C, 
60s 98C, 30s 52C, 60s 72C, 2:40 
72C, 5 
min 
PCR7e 
(5’ gB, 
BirA 
pg 23 
Q5, GC 
enhancer 
pCAGGS-
HSV1-gB 
rSC89, 
rSC57 
98C, 
30s 98C, 10s 71C, 30s 72C, 1:45 
72C, 2 
min 
PCR8n 
(5’ gB, 
AP) 
pg 26 
Q5, GC 
enhancer 
pCAGGS-
HSV-gB 
rSC18, 
rSC58 
98C, 
30s 98C, 10s 70C, 30s 72C, 2:15 
72C, 2 
min 
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Table 3. Optimal PCR conditions to amplify fragments of glycoprotein with tag 
 
 Cycle 30X  
Fragment Enzyme Template Primers 
Initial 
Den. Denature Anneal. Extension 
Final 
Ext. 
PCR11b 
(gH-BirA) 
pg 33 
Vent 5, 1d rSC22, rSC25b 98C 1m 98C, 30s 54C, 1m 72C, 4m 72C, 5m 
PCR12d 
(gH-APm) 
pg 34 
Vent 6, 3 rSC22, rSC28b 98C 1m 98C, 30s 57C, 1m 72C, 4m 72C, 5m 
PCR13e 
(F-BirA) 
pg 41 
Q5, no 
enhancer 9, 2e 
rSC90, 
rSC25c 98C 1m 98C, 30s 70C, 3m 72, 1:40m 72C, 2m 
PCR14 (F-
APm) pg 4 Vent 10, 4 
rSC90, 
rSC28c 98C, 1m 98C, 30s 52C, 1m 72C, 4m 72, 5m 
PCR15k 
(gB-BirA) 
pg 26 
Q5, with 
enhancer 7e, 1d 
rSC89, 
rSC25b 98C, 30s 98C, 10s 70C, 30s 72C, 2:15 72C, 2m 
PCR16j 
(gB-APm) 
pg 27 
Q5, no 
enhancer 8n, 3 
rSC18, 
rSC28b 98C, 30s 98C, 10s 71C, 30s 72C, 2:15 72C, 5m 
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Table 4. Confirmation of ligation of the PCR fragments into pSG5 vector. 
 
Fragment 
Lab 
Notebook 
Page 
Restriction 
Enzyme(s) 
Expected 
product Date Agarose Gel  
PCR11b 
(gH-BirA) 40 XbaI 1292 2/13/14 
                   L                                   1         2         3 
 
PCR12d 
(gH-APm) 
Colony 
screen 
45  2.5 kb 3/26/14 
    kB                    L        1          2          3 
 
PCR13e 
(F-BirA) 
Colony 
screen 
47  2.6 kb 3/26/14 
                                 L                  1                 2 
 
PCR14 (F-
APm) 
 
31 BglII 4933, 463, 361 1/7/14 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  L	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  **	  
 
** This is the lane with the correct insert. 
PCR15k 
(gB-BirA) 39 NotI, BglII 3585 1/28/14 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  L           1 
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PCR16j 
(gB-APm) 39 NotI, BglII 2678 1/31/14 
        kB                            L          1         2           3 
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